CELESTIAL

NCT01908426 📎

Regimen

Experimental
cabozantinib 60 mg/day
Control
placebo

Population

Previously treated advanced hepatocellular carcinoma after prior sorafenib, up to 2 prior systemic regimens

Key finding

mOS 10.2 vs 8.0 mo (HR 0.76, 95% CI 0.63-0.92, p=0.005); mPFS 5.2 vs 1.9 mo (HR 0.44); ORR 4% vs <1%; allowed up to 2 prior lines (broader than REACH-2/RESORCE); etiology HBV 38%, HCV 24%

Source: PMID 29972759

Timeline

    Guideline citations

    • NCCN HCC (p.69)